US · PVLA
Palvella Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Wayne, PA 19087
- Website
- palvellatx.com
Price · as of 2024-12-31
$126.84
Market cap 1.6B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $243.20 | ||||
| 2022 | $116.80 | $95.92 | $0.00 | $0.00 | $311.34 |
| 2023 | $13.92 | $244.95 | |||
| 2024 | $29.00 |
AI valuation
Our deep-learning model estimates Palvella Therapeutics, Inc.'s (PVLA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $126.84
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PVLA | Palvella Therapeutics, In… | $126.84 | 1.6B | — | — | — | — | -3.70 | 1.03 | — | 1.45 | — | 1.03 | 0.00% | — | — | -59.37% | 87.48% | -36.40% | 0.00 | -3.26 | 7.33 | 7.14 | 6.37 | -15312.00% | — | -2089.00% | -16.79% | -0.90 | 67.28% | 0.00% | 0.00% | 118.12% | 1.35 | 1.76 | — | 0.53 |
| ABUS | Arbutus Biopharma Corpora… | $4.66 | 896.23M | +556% | -71% | — | +345% | -8.79 | 6.31 | 99.56 | -7.21 | — | 6.31 | 100.00% | -1236.74% | -1133.04% | -68.76% | 433.24% | -50.65% | 0.01 | -557.07 | 8.15 | 8.01 | 0.51 | -1364.00% | -6598.00% | -2520.00% | -10.59% | -4.15 | 369.16% | 0.00% | 0.00% | 2.84% | -6.46 | -7.58 | 79.89 | -4.43 |
| EYPT | EyePoint Pharmaceuticals,… | $17.56 | 1.45B | +9,195% | -75% | — | — | -3.07 | 1.19 | 9.28 | -0.41 | -11.16 | 1.19 | 91.42% | -337.06% | -302.43% | -43.42% | 403.05% | -33.83% | 0.06 | -10418.14 | 7.81 | 7.57 | 0.60 | 2747.00% | -597.00% | 800187.00% | -32.46% | -2.57 | 360.01% | 0.00% | 0.00% | 0.00% | -0.36 | -0.40 | 1.21 | -0.07 |
| GHRS | GH Research PLC | $14.85 | 921.14M | — | — | — | — | -14.02 | 3.05 | — | -10.30 | -136.21 | 3.05 | 0.00% | — | — | -19.58% | -113.53% | -18.80% | 0.00 | -70.17 | 17.23 | 16.87 | 2.60 | 1029.00% | — | 2661.00% | -7.75% | -4.72 | -95.53% | 0.00% | 0.00% | 4.16% | -7.90 | -9.39 | — | 34.41 |
| KURA | Kura Oncology, Inc. | $8.73 | 759.66M | — | — | — | — | -3.73 | 1.57 | 12.04 | 0.37 | — | 1.57 | 100.00% | -358.55% | -322.89% | -42.91% | 126.01% | -28.78% | 0.04 | -119.33 | 9.46 | 9.24 | 1.23 | -288.00% | — | -20708.00% | 20.63% | 1.71 | -87.30% | 0.00% | 0.00% | 28.94% | 0.32 | -0.46 | -1.15 | -0.24 |
| NBTX | Nanobiotix S.A. | $31.04 | 1.5B | +16% | -96% | — | +542% | -1.99 | -2.06 | -11.65 | -2.34 | -5.96 | -2.06 | 100.00% | 589.13% | 586.89% | 201.73% | 150.15% | -84.47% | -0.77 | -8.46 | 1.04 | 0.99 | -0.02 | 3333.00% | -13206.00% | 5921.00% | -15.08% | -0.33 | 44.78% | 0.00% | 0.00% | 0.00% | -2.00 | -6.69 | -11.75 | -4.28 |
| PROK | ProKidney Corp. | $2.24 | 277.76M | — | — | — | — | -0.63 | -0.10 | 1352.79 | 1.59 | -7.18 | -0.10 | 100.00% | -241678.95% | -80507.89% | 15.57% | 13.02% | -37.91% | 0.00 | -20408.44 | 10.93 | 9.96 | 0.60 | 877.00% | — | 2542.00% | -151.60% | -3.49 | 11.09% | 0.00% | 0.00% | 38.56% | 1.37 | 1.62 | -3319.00 | -2.64 |
| RZLT | Rezolute, Inc. | $3.21 | 307.19M | — | — | — | — | -8.17 | 3.75 | — | -5.53 | — | 3.75 | 0.00% | — | — | -52.56% | 2059.39% | -48.28% | 0.01 | — | 14.37 | 14.09 | 1.16 | -2632.00% | — | 2041.00% | -11.36% | -5.80 | 1780.51% | 0.00% | 0.00% | 4.00% | -5.53 | -6.40 | — | 23.66 |
| SPRY | ARS Pharmaceuticals, Inc. | $9.30 | 919M | +490,701% | +105,472% | -67% | +252,078% | 131.50 | 4.10 | 11.80 | -245.60 | — | 4.22 | 76.94% | -3.46% | 8.97% | 3.28% | 10.92% | 2.74% | 0.00 | — | 14.26 | 13.79 | 16.90 | -11370.00% | 29706333.00% | -12185.00% | 1.23% | 0.58 | -47.64% | 0.00% | 0.00% | 0.00% | -239.31 | 56.82 | 8.28 | 7.48 |
| SVRA | Savara Inc. | $6.02 | 1.22B | — | — | — | — | -5.37 | 3.01 | — | -3.38 | -11.82 | 3.20 | 0.00% | — | — | -61.50% | -3224.37% | -49.11% | 0.16 | — | 13.73 | 13.40 | -0.11 | 4545.00% | — | 7352.00% | -17.29% | -6.05 | -2784.35% | 0.00% | 0.00% | 0.19% | -3.35 | -3.88 | — | 3.70 |
| TYRA | Tyra Biosciences, Inc. | $33.31 | 1.78B | — | — | — | — | -7.24 | 1.82 | — | -2.80 | — | 1.82 | 0.00% | — | — | -31.60% | -1368.86% | -29.34% | 0.02 | — | 23.81 | 23.53 | 0.83 | -679.00% | — | 3836.00% | -11.25% | -4.78 | -925.54% | 0.00% | 0.00% | 5.54% | -2.79 | -4.13 | — | 17.59 |
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
- CEO
- Wesley H. Kaupinen
- Employees
- 14
- Beta
- -0.16
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $126.84) − 1 = — (DCF, example).